VGM & ASSOCIATESHealthcare MSO
Full Menu Search

The PHE Will End May 11

Published in Government Relations on January 31, 2023

President Biden has announced that the COVID-19 Public Health Emergency (PHE) will officially end on May 11, 2023. This PHE was initially announced in early 2020 and has been renewed in multiple 90-day increments since then, most recently on Jan. 11.  

What Ending the PHE Means for DMEPOS Suppliers 

There are several provisions which impact the DMEPOS industry tied to the duration of the PHE. With the official ending of the PHE now in sight, most of those provisions and waivers that are still in place will end on May 11, 2023. Those waivers impacted signature/documentation requirements, reimbursement methodology, and modified medical policies (LCD), etc. A full list of all waivers can be found here, and the waivers specific to DMEPOS suppliers can be found here.  

For those beneficiaries that received equipment with a waiver, we are still awaiting direction from CMS. When we met with CMS in the past to share concerns regarding patients in the post-PHE transition, CMS representatives indicated they would provide ample time with instruction. Once we receive this direction from CMS and the local DME MACs, we will provide the information to the supplier community.  

In the meantime, start running reports in your billing software looking for those claims with the CR modifier and claim narrative (COVID-19). Know the status of those beneficiaries and claims in preparation for any instruction we shall receive. 

Regarding the 75/25 blended reimbursement rates for providers serving Medicare beneficiaries in non-rural, non-competitive bid areas, these rates will not expire with the PHE, as first intended. Introduced and implemented by CMS after the passage of the CARES Act in March 2020, these increased reimbursement rates were initially tied to the PHE, meaning they would go away as soon as the PHE was officially ended. However, the Omnibus bill passed at the end of 2022 ensured that those 75/25 blended rates would remain in place through the end of 2023 if the PHE ended during 2023.  

That means that reimbursement for DMEPOS providers will be as follows: 

  • Providers serving Medicare beneficiaries located within CBAs will continue to receive the CBA rates (the higher blended rates were never applied in these areas). 
  • Providers serving Medicare beneficiaries located in non-rural, non-competitive bid areas will receive the 75/25 blended rates for dates of service up to and including Dec. 31, 2023. On Jan. 1, 2024, those blended rates will end, and reimbursement will revert to rates similar to what was in place prior to the PHE. Those pre-pandemic rates, however, will be adjusted based on the CPI-U increases for 2022 (between 5.1 and 5.4%) and 2023 (between 6.4 and 9.1%). 
  • Providers serving Medicare beneficiaries in rural areas will continue to receive the 50/50 blended rates indefinitely. These rural rates have been in place since 2018, prior to the PHE declaration, and will remain in effect until further rulemaking changes them. They will not end when the PHE does, nor will they end on Dec. 31, 2023, with the 75/25 blended rates. 

As always, the experts in VGM Government Relations will continue to monitor the changes and updates and communicate additional details as needed. Feel free to contact us with any questions related to this topic.  

TAGS

  1. phe
  2. vgm
  3. vgm government

Get Connected

Stay up-to-date on the latest resources and news provided by VGM & Associates.

Sign Up for Email

From Our Experts

Bipartisan Medicare O&P Bill Introduced thumbnail Bipartisan Medicare O&P Bill Introduced In a timely move ahead of next week's NAAOP Legislative Fly-In, a bipartisan group of lawmakers introduced the Medicare Orthotics and Prosthetics Patient-Centered Care Act, a bill aimed at improving access to high-quality orthotic and prosthetic care for Medicare beneficiaries. The Patient-Centered Care Act seeks to address critical gaps in Medicare coverage for orthotic and prosthetic (O&P) services. Under current rules, beneficiaries may receive devices without the necessary clinical services Proposed Rule Suggests Significant Change To Accreditation Process thumbnail Proposed Rule Suggests Significant Change To Accreditation Process The recently released proposed rule CMS-1828-P contains a significant change that could reshape how suppliers navigate accreditation. The rule proposes a major change that would require suppliers to be surveyed and reaccredited annually instead of the current three (3) year cadence. This proposal raises substantial questions about both operational feasibility and cost implications. August Of Action: Your Chance To Connect With Congress thumbnail August Of Action: Your Chance To Connect With Congress It's time to take advantage of August Of Action—a perfect opportunity to make your voice heard. Every summer, federal legislators return to their home states during the Congressional recess. While it gives them a break from Washington D.C., it's primarily a time for them to connect with constituents like you. HR1 Passes House, Advances to President Trump's Desk for Signature thumbnail HR1 Passes House, Advances to President Trump's Desk for Signature After extensive negotiations and partisan debate, the House has officially passed HR1, clearing the path for the bill to be signed into law by President Donald Trump. The legislation, which aims to reduce federal healthcare expenditures, contains several provisions that may impact the durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) industry. CMS files the Proposed Rule that sheds light on the next round of the Competitive Bidding Program thumbnail CMS files the Proposed Rule that sheds light on the next round of the Competitive Bidding Program On June 30, 2025, CMS filed the anticipated Proposed Rule that includes updates to the Competitive Bidding Program (CBP). Public comments are due 60 days from June 30, 2025. Below is a high-level summary of the rule. It is critical to note that, according to the Proposed Rule Fact Sheet dated June 30, 2025, CMS has stated that they have not announced the specific product categories they are bidding or the specific timeframe for the next competition. Those specifics will be forthcoming in a fu Senate Narrowly Passes HR1, Sending It Back to House for Final Approval thumbnail Senate Narrowly Passes HR1, Sending It Back to House for Final Approval President Donald Trump's sweeping legislative package, formally titled the One Big, Beautiful Bill Act, now referred to as HR1., cleared the Senate today in a dramatic 51–50 vote, with Vice President JD Vance casting the tie-breaking vote. The bill now returns to the House, where lawmakers must decide whether to adopt the Senate's revised version or negotiate further changes before it can reach the president's desk. Several Prominent Medicaid Provisions in Senate's Budget Bill Deemed in Violation of Byrd Rule thumbnail Several Prominent Medicaid Provisions in Senate's Budget Bill Deemed in Violation of Byrd Rule Senate Parliamentarian Elizabeth MacDonough advised this week that multiple Medicaid provisions in the Senate's reconciliation bill would violate Senate procedure by violating the Byrd Rule. The Byrd Rule is a Senate-specific procedural process that allows Senators to prevent or block inclusion of extraneous provisions in reconciliation bills. Other provisions are still under review. Evaluating the Value of a Payer Contract thumbnail Evaluating the Value of a Payer Contract In our last article, Key Payers Denied Your Application Citing Their Network Is Closed – Now What?, we discussed strategies for addressing payer contracting denials due to a closed network. As indicated, this process can be an extremely time-consuming exercise with no guarantees and mixed results. Below are a few things to consider as you evaluate whether a contract is worth the extra effort.

Give your business an advantage over the competition.

Become a Member